The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel will discuss:
- When is the right time to get acquired?
- What is the survival rate of c-suite after an acquisition?
- Why is an acquisition better than a collaboration?
- What are the key issues in the due diligence process that can hurt the value of the deal?
- How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
- What types of steps can be taken to prepare a forecast that drives value negotiations
- How can this analysis be leverage in negotiating a collaborative or co-partner agreement
Panelists include: Ben Clark, Partner, Deloitte & Touche LLP; Jay Jesclard, Senior Manager, Deloitte Financial Advisory Services LLP; Linda Justice, Senior Manager, Deloitte Financial Advisory Services LLP; and Ronda Sroka, Partner, Deloitte Tax LLP.
Related Insights
23 December 2024
Labor & Employment Law Perspectives
Regulating Artificial Intelligence in Employment Decision-Making: What’s on the Horizon for 2025
Share on TwitterShare by EmailShareBack to topEmployment law in 2024 could aptly be summarized as the “Year of Artificial Intelligence Legislation.
23 December 2024
Injunction Stayed: Corporate Transparency Act Enforcement Resumes
The U.S. Department of Justice scored a victory in ongoing litigation over the constitutionality of the Corporate Transparency Act (CTA) when the Fifth Circuit Court of Appeals stayed the nationwide preliminary injunction issued earlier this month by a federal district court in Texas.
23 December 2024
Health Care Law Today
Medicare Telehealth Flexibilities Get a Three-Month Lifeline
Share on TwitterShare by EmailShareBack to topAfter much uncertainty, Congress has extended many Medicare telehealth flexibilities through March 31, 2025, in its end-of-year appropriations bill.